Fenwick represented MRL Ventures, the therapeutics-focused
corporate venture fund of Merck & Co., in its investment in VectorY’s $138
million Series A financing, one of the largest private biotech financings in
Europe in 2023. The round was co-led by EQT Life Sciences and the Forbion
Growth Opportunities Fund.
biotech company developing innovative vectorized antibody therapies for the
treatment of neurodegenerative diseases, will use the proceeds to support the
clinical development of VTx-002, its lead vectorized antibody program targeting
TDP-43 for the treatment of ALS. More information can be obtained from the company’s announcement.
transaction was led by corporate partner Ian Goldstein and associates Serena
Ward and Ty Chung.